AirStrip is a respected innovator that we have worked with for several years.

HCA’s Health Insight Capital subsidiary committed to AirStrip alongside the expansion of HCA and AirStrip’s commercial collaboration. Wellness Insight Capital makes equity investments in early stage businesses that are chosen to supply innovative solutions for make use of in HCA’s functions. AirStrip is a respected innovator that we have worked with for several years, said R. Milton Johnson, HCA’s President and Chief Financial Officer. Our collaboration with AirStrip promotes quality individual care by offering physicians the latest technology to access real-time patient data on mobile devices, while our investment facilitates the growth of AirStrip’s system and capability.Today Earlier, the Austrian organization Affiris GmbH, based in Vienna, announced that it has been granted a Europe-wide patent for a pool of peptide sequences that are of key importance to a forward thinking Alzheimer’s vaccine. The business can use these patented components to produce an optimized vaccine against beta-amyloid newly, the peptide responsible for the onset of Alzheimer’s disease. Dr. Walter Schmidt, CEO of Affiris GmbH, feedback on the importance of the patent: This patent can be an ideal addition to the Affiris patent portfolio. Our safeguarded AFFITOME technology allows us to target the relevant structures of human rogue proteins. Our specific active substances are referred to as AFFITOPE, as the entire spectrum of possible substances is referred to as AFFITOME.